Rx-To-OTC Switch Candidate Negative Lists "Stifle Innovation" - CHPA
This article was originally published in The Tan Sheet
Executive Summary
FDA should consider all Rx-to-OTC switch candidates on a case-by-case basis and avoid creating "presumptive negative lists" of drug classes not suited to OTC use, the Consumer Healthcare Products Association stresses in Aug. 25 comments to the agency.